Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Li-Yuan Bai

Showing results (121-130 of 139) with videos related to

Pageof 14
Sort By:
Biorxiv : the Preprint Server for Biology|November 1, 2024
All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancerChing-Fei Li, Li-Yuan Bai, Yongkun Wei, et al.
Cancer Medicine|January 11, 2017
A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practicePo-Han Lin, Huei-Ying Li, Sheng-Chih Fan, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|August 20, 2024
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trialNarikazu Boku, Takeshi Omori, Kohei Shitara, et al.
Lancet (London, England)|October 11, 2017
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trialYoon-Koo Kang, Narikazu Boku, Taroh Satoh, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 16, 2019
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancerTaroh Satoh, Yoon-Koo Kang, Yee Chao, et al.
The Lancet. Gastroenterology & Hepatology|June 21, 2024
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trialYoon-Koo Kang, Masanori Terashima, Young-Woo Kim, et al.
The Lancet. Oncology|January 14, 2022
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trialYoon-Koo Kang, Li-Tzong Chen, Min-Hee Ryu, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|December 22, 2019
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update dataLi-Tzong Chen, Taroh Satoh, Min-Hee Ryu, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 20, 2021
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumabNarikazu Boku, Taroh Satoh, Min-Hee Ryu, et al.
Journal of Hepatology|February 20, 2025
A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancerJennifer J Knox, Mairéad G McNamara, Igor S Bazin, et al.
Pageof 14

Showing results (121-130 of 139) with videos related to

Sort By:
Pageof 14
Biorxiv : the Preprint Server for Biology|November 1, 2024
All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancerChing-Fei Li, Li-Yuan Bai, Yongkun Wei, et al.
Cancer Medicine|January 11, 2017
A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practicePo-Han Lin, Huei-Ying Li, Sheng-Chih Fan, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|August 20, 2024
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trialNarikazu Boku, Takeshi Omori, Kohei Shitara, et al.
Lancet (London, England)|October 11, 2017
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trialYoon-Koo Kang, Narikazu Boku, Taroh Satoh, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 16, 2019
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancerTaroh Satoh, Yoon-Koo Kang, Yee Chao, et al.
The Lancet. Gastroenterology & Hepatology|June 21, 2024
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trialYoon-Koo Kang, Masanori Terashima, Young-Woo Kim, et al.
The Lancet. Oncology|January 14, 2022
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trialYoon-Koo Kang, Li-Tzong Chen, Min-Hee Ryu, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|December 22, 2019
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update dataLi-Tzong Chen, Taroh Satoh, Min-Hee Ryu, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 20, 2021
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumabNarikazu Boku, Taroh Satoh, Min-Hee Ryu, et al.
Journal of Hepatology|February 20, 2025
A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancerJennifer J Knox, Mairéad G McNamara, Igor S Bazin, et al.
Pageof 14